AstraZeneca Awards Funding to Eight Innovative Research Projects From Early-Career Scientists Around the World in Second R&D Postdoctoral Challenge
AstraZeneca announced today eight winners of the 2023 R&D Postdoctoral Challenge and agreed to fund their postdoctoral positions at one of the Company’s strategic R&D centres in either Cambridge, UK, Gaithersburg or Boston, US or Gothenburg, Sweden.
The R&D Postdoctoral Challenge stands out among traditional industry postdoctoral initiatives which usually offer pre-defined projects. The unique programme from AstraZeneca, now running for a second year, enables early-career scientists from anywhere in the world to submit and potentially pursue their own novel research proposals within the Company. With the support of highly skilled and multidisciplinary research teams, the winners will pursue their unique research projects to ultimately accelerate drug discovery for some of the world’s most complex rare and chronic diseases. By encouraging diverse thinking and global collaboration, AstraZeneca pushes the boundaries of science to deliver life-changing medicines.
After being short-listed from nearly 100 applicants, eight finalists presented their research proposals in a live event at AstraZeneca’s Discovery Centre (DISC), located in Cambridge, UK. After presenting to a judging panel comprising AstraZeneca and external life science leaders, the winners were selected based on scientific merit and potential to create a real impact for patients.
Dr Jenni Nordborg, Director, International Affairs, Lif said: “I was captivated by the pitches and seeing the novel approaches that each and every one of the finalists presented on stage. But even more than that, I was inspired by their enthusiasm and passion for their focus area of science, and their commitment to research that will improve outcomes for patients.”
Dr Sharon Barr, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca, said: “Scientific progress depends on our ability to foster a community that encourages new ideas and fresh perspectives from the next generation of leading scientists. We are thrilled to welcome the eight winners to AstraZeneca; this unique programme demonstrates our commitment to supporting early talent and science led innovation.”
Dr Seng Cheng, Senior Vice President, Research and Product Development, Alexion, said: “The winners are all united by their willingness to step away from the norm and pursue a programme that is completely changing the traditional postdoc scheme. They bring the passion and enthusiasm to innovate, as well a collective ambition to accelerate drug discovery.”
With fully funded AstraZeneca postdoctoral research positions, the winners gain access to the Company’s expertise, compounds, novel tools and technologies, as well as mentoring support to turn their innovative ideas into solutions that could benefit patients around the world.
As part of AstraZeneca’s Early Talent programmes, the R&D Postdoctoral Challenge supports the commitment to early career scientists by nurturing talent and providing opportunities to work within a diverse and inclusive environment that enables science to thrive.
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MSCI Appoints Jana Haines as Head of Index30.11.2023 15:14:00 CET | Press release
MSCI Inc. (NYSE: MSCI), a leading provider of mission-critical decision support tools and services for the global investment community, today announced that Jana Haines has joined the firm as Head of Index and as a member of MSCI’s Executive Committee. Based in New York, Ms. Haines will be responsible for the strategic development and execution of MSCI’s global Index product line. She will partner with senior leaders across the firm to manage the Index product development process. Ms. Haines will aim to drive innovation across index categories, including market cap, sustainability, climate, factors, thematics and asset classes, such as fixed income and private assets. "As a longtime business leader, Jana has a proven track record of strategic thinking and a unique understanding of the value of MSCI’s indexes to investors,” said Baer Pettit, President and Chief Operating Officer of MSCI. “Jana’s extensive expertise in the global financial industry will be critical to MSCI building an ev
Empatica Announces Plans for Landmark Clinical Study to Develop an AI-Based Seizure Forecast Based on Wearable Real-World Data30.11.2023 14:29:00 CET | Press release
Empatica, a digital health and AI company developing medical-grade wearables and digital biomarkers for health monitoring and diagnostics, today announced plans to launch a first-of-its-kind study aimed at developing a seizure forecasting algorithm for people living with epilepsy, based on real-world data collected using its technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231130692933/en/ Empatica announces plans to develop an AI-based seizure forecasting algorithm based on wearable real-world Data (Graphic: Business Wire) More than 3 million Americans suffer from epilepsy, according to numbers from the Centers for Disease Control. And around one third of people with epilepsy have refractory epilepsy which occurs when medications no longer control seizures1. Epileptic seizures are disruptive health events that can have a significant negative impact on quality of life and increase risk of injury and death for peopl
QPS Holdings, LLC divests its Neuropharmacology Business Unit30.11.2023 14:15:00 CET | Press release
Today QPS Holdings, LLC (QPS) a leading drug development Contract Research Organization (CRO), announces an agreement to sell its Neuropharmacology business unit (QPS Neuropharmacology) to Scantox, a leading Nordic pre-clinical, GLP-accredited CRO. QPS Neuropharmacology, based in Grambach, Austria and focused on drug discovery, specializes in neurodegenerative diseases, rare diseases and mental disorders. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231130940694/en/ QPS Neuropharmacology facility in Grambach, Austria. (Graphic: Business Wire) Founded in 1999, QPS Neuropharmacology has built a strong global reputation for high quality services that are deeply scientifically rooted and has an undisputed track-record of serving a loyal and broad customer base globally. This long history of developing expertise within neuropharmacology preclinical studies has contributed to strong year-on-year growth and positioned the organiz
ASICS Teams Up with BlueConic for Enhanced Personalization and Data Privacy Compliance30.11.2023 13:00:00 CET | Press release
ASICS, the global leader in athletic footwear and apparel, has selected pure-play customer data platform (CDP) BlueConic to reimagine the way it engages with customers. The move will empower the ASICS team to support a growing number of personalization projects while remaining compliant with consumer data privacy regulations around the globe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231128796155/en/ ASICS teams up with BlueConic to deliver personalization at scale. (Photo: Business Wire) With operations across the Americas, Europe, the Middle East, Asia, and Oceania, ASICS is best known for its sports apparel, shoes, equipment, and accessories for men, women, and children. The company acquired fitness app RunKeeper in 2016 for its potential as a one-on-one marketing channel. With a focus on increasing engagement and loyalty both within the app and across brands, channels, and regions, ASICS will use BlueConic to unify
LTIMindtree Partners with Metasphere to Deliver Smart Sewers Solutions30.11.2023 12:00:00 CET | Press release
LTIMindtree [NSE: LTIM, BSE: 540005], a global technology consulting and digital solutions company, announced that it has been selected as a strategic partner by Metasphere, a wastewater application specialist, to scale their Smart Sewers management platform. As a part of this engagement, LTIMindtree will transform Metasphere’s next-generation wastewater monitoring solution portfolio, and enable scalable delivery and platform to their customers. Metasphere, part of Grundfos, provides smart network management solutions to the global utility industry. The company helps customers prevent leaks and spills for a cleaner, greener world and has deployed more than 200K sensors for their customers worldwide. By leveraging cutting-edge technology, the company offers intelligent, innovative, all-in-one wastewater application solutions. These solutions provide full network visibility, performance and forecasting that reduce telemetry ownership cost for customers to manage time-critical remote asse